Sandoz announced the launch of Symjepi (epinehprine) injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis. It was initially approved by the Food and Drug Administration (FDA) in June 2017.
Symjepi delivers 0.3mg epinephrine injection and is intended for patients who weigh 30kg or more. It can be injected intramuscularly or subcutaneously, and through clothing if necessary. Symjepi should only be injected into the anterolateral aspect of the thigh; injection into other areas such as the buttocks or the hands and feet may result in adverse effects and may also not provide effective treatment of anaphylaxis.
Symjepi is supplied as 0.3mg single-dose, prefilled syringes in 2-count cartons. The product will be made available first in institutions followed by a launch in the retail setting. “The Symjepi device is small in size and fits into the palm of your hand, with the goal of a simple-to-use application and intuitive, user-friendly design,” said Carol Lynch, President of Sandoz Inc.
For more information call (858) 997-2400 or visit Sandoz.com.
This article originally appeared on MPR